Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
ViewAttendees 3

C11. UTIs

Session: UTIs

194 - Progression of an Uncomplicated Urinary Tract Infection Among Female Patients with Susceptible and Non-Susceptible Urine Isolates: Findings from an Integrated Delivery Network

On Demand
Participants should be aware of the following financial/non-financial relationships:
Jason Shafrin, PhD: Precision Medicine Group (Employee, Former employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)
Alen Marijam, MSc: GlaxoSmithKline plc. (Employee, Shareholder)
Ashish V. Joshi, PhD: GlaxoSmithKline plc. (Employee, Shareholder)
Fanny S. Mitrani-Gold, MPH: GlaxoSmithKline plc. (Employee, Shareholder)
Katie Everson, MSc: Precision Medicine Group (Employee, Employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)
Rifat Tuly, MPH: Precision Medicine Group (Employee, Employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)
Peter Rosenquist, MSc: Precision Medicine Group (Employee, Employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)
Michael Gillam, MD: MedStar Health (Employee, Employee of MedStar Health and received funding from GlaxoSmithKline plc. through Precision Medicine Group to conduct this study)
Maria Elena Ruiz, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

    Presenting Author(s)

  • Jason Shafrin, PhD

    Senior Managing Director
    FTI Consulting
    Los Angeles, CA, United States

    Precision Medicine Group (Employee, Former employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)

    Slides Slides and Audio

    • Co-Author(s)

  • AM

    Alen Marijam, MSc

    GlaxoSmithKline plc., Collegeville, PA, USA
    Collegeville, Pennsylvania, United States

    GlaxoSmithKline plc. (Employee, Shareholder)

  • AJ

    Ashish V. Joshi, PhD

    Senior Director
    GlaxoSmithKline plc, Collegeville, PA, USA
    Philadelphia, Pennsylvania, United States

    GlaxoSmithKline plc. (Employee, Shareholder)

  • FM

    Fanny S. Mitrani-Gold, MPH

    Director, Epidemiology
    GlaxoSmithKline plc, Collegeville, PA, USA
    Chicago, Illinois, United States

    GlaxoSmithKline plc. (Employee, Shareholder)

  • KE

    Katie Everson, MSc

    PRECISIONheor, Austin, TX, USA
    Austin, Texas, United States

    Precision Medicine Group (Employee, Employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)

  • RT

    Rifat Tuly, MPH

    PRECISIONxtract, Los Angeles, CA, USA
    Los Angeles, California, United States

    Precision Medicine Group (Employee, Employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)

  • PR

    Peter Rosenquist, MSc

    PRECISIONheor, Washington, DC, USA
    Bethesda, Maryland, United States

    Precision Medicine Group (Employee, Employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc. to conduct this study)

  • MG

    Michael Gillam, MD

    MedStar Health, Washington, DC, USA
    Washington, DC, Washington, United States

    MedStar Health (Employee, Employee of MedStar Health and received funding from GlaxoSmithKline plc. through Precision Medicine Group to conduct this study)

  • Maria Elena Ruiz, MD

    Director of Transplant Infectious Diseases, Assistant Section Chief of Infectious Diseases, Department of Medicine
    MedStar Washington Hospital Center, Washington, DC, USA
    Washington, DC, DC, United States

    MedStar Health (Employee, Employee of MedStar Health and received funding from GlaxoSmithKline plc. through Precision Medicine Group to conduct this study)